RPN2 and neoplasm: Here we show that administration of ABT-737 can overcome the radioresistance in RPN2 overexpressed GBM cells, suggesting that inhibition of MCL1 could be a therapy strategy for GBM patients with abnormal tumor RPN2 expression.